Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
|Articles|January 2, 2022
- Pharmaceutical Technology, January 2022 Issue
- Volume 46
- Issue 1
Digital Integration Platform
Author(s)Pharmaceutical Technology Editors
Scitara’s Scientific Integration Platform (SIP) establishes a flexible, adaptable framework that facilitates a fully connected laboratory.
Scitara’s Scientific Integration Platform (SIP) is a cloud-native infrastructure designed to realize the full benefits of digital transformation. SIP establishes a flexible, adaptable framework that facilitates a fully connected laboratory and an in-situ configurable platform. Its flagship technology, the Scitara Digital Lab Exchange, forms an independent, vendor-agnostic integration layer.
SIP enables laboratories and science-based organizations to access the advantages of data mobility, independent of any digital platforms that have already been deployed. It automates scientific data exchange across various endpoints and interfaces existing various informatics platforms, as well as instrument-specific analysis systems.
Articles in this issue
almost 5 years ago
Industrious Pharmaceuticalsalmost 5 years ago
The Long Path to Normalalmost 5 years ago
Changes Afoot: 2022 Outlook for Pharma and its Peoplealmost 5 years ago
Addressing the Training Gap for Single-Use Technologiesalmost 5 years ago
The Need for Speed: How Operation Warp Speed Shifted the Pharma Industryalmost 5 years ago
Taste and Appearance: Selecting the Right Excipientsalmost 5 years ago
Tackling the Big Issue of Solubilityalmost 5 years ago
Biologics Testing Highlights Need for Analytical Skillsalmost 5 years ago
Outsourcing’s Race Toward Noveltyalmost 5 years ago
Regulating Digital TherapeuticsRelated to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5